Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy
Promising reduction (>95%) in seizure frequency at the key one-year post treatment endpoint in the…